Neurosense Therapeutics Ltd Corporate and Clinical Update Call Transcript - Thomson StreetEvents

Neurosense Therapeutics Ltd Corporate and Clinical Update Call Transcript

Neurosense Therapeutics Ltd Corporate and Clinical Update Call Transcript - Thomson StreetEvents
Neurosense Therapeutics Ltd Corporate and Clinical Update Call Transcript
Published Dec 08, 2025
10 pages (5217 words) — Published Dec 08, 2025
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of NRSN.OQ conference call or presentation 8-Dec-25 1:30pm GMT

  
Brief Excerpt:

...(technical difficulty) Working hard to take into account everything that that and expand previous findings and support the future success of prime. With recent FDA clearance of our study, we are fully committed to meeting our timelines. The second topic is the pre-NDS meeting with Health Canada. Following productive discussions with the agency. I'm glad to share that we are now back on track and believe we can advance the submission for conditional approval in Canada with the new data that we have generated. The third topic is the proof of concept Phase 2 program in Alzheimer's disease. We have recently completed a database log of our proof of concept study which we just announced today, and we anticipate top-line results in the first quarter of 2026. We look forward to assessing the data to better understand if we may be able to address unmet needs in Alzheimer's. And the last topic for today is the partnership discussions. We recognize the importance of providing our investors and supporters...

  
Report Type:

Transcript

Source:
Company:
Neurosense Therapeutics Ltd
Ticker
NRSN.OQ
Time
1:30pm GMT
Format:
PDF Adobe Acrobat
Buy Now

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Neurosense Therapeutics Ltd Corporate and Clinical Update Call Transcript" Dec 08, 2025. Alacra Store. Nov 06, 2026. <http://www.alacrastore.com/thomson-streetevents-transcripts/Neurosense-Therapeutics-Ltd-Corporate-and-Clinical-Update-Call-T16556760>
  
APA:
Thomson StreetEvents. (2025). Neurosense Therapeutics Ltd Corporate and Clinical Update Call Transcript Dec 08, 2025. New York, NY: Alacra Store. Retrieved Nov 06, 2026 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Neurosense-Therapeutics-Ltd-Corporate-and-Clinical-Update-Call-T16556760>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.